Amista Labs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-12-2024
- Paid Up Capital ₹ 0.10 M
as on 07-12-2024
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -15.14%
(FY 2022)
- Profit -62.40%
(FY 2022)
- Ebitda -623.54%
(FY 2022)
- Net Worth -14.51%
(FY 2022)
- Total Assets -7.90%
(FY 2022)
About Amista Labs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Raman Lamba and Jugal Sharma serve as directors at the Company.
- CIN/LLPIN
U24232CH2014PTC035099
- Company No.
035099
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Amista Labs Private Limited offer?
Amista Labs Private Limited offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antibacterial Drugs, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Ayurvedic,Herbal Products & Medicine, Ayurvedic Pain Relief Oil, Ayurvedic Herbal Syrups & Tonics.
Who are the key members and board of directors at Amista Labs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raman Lamba  | Director | 13-Jun-2014 | Current |
| Jugal Sharma | Director | 13-Jun-2014 | Current |
Financial Performance of Amista Labs.
Amista Labs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 15.14% decrease. The company also saw a substantial fall in profitability, with a 62.4% decrease in profit. The company's net worth observed a substantial decline by a decrease of 14.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amista Labs?
In 2022, Amista Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Amista Labs?
Unlock and access historical data on people associated with Amista Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amista Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amista Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
